Lamivudine/tenofovir disoproxil fumarate vs emtricitabine/tenofovir disoproxil fumarate, both administered with efavirenz, in antiretroviral-naive Zambian patients with HIV-1 infection.

Trial Profile

Lamivudine/tenofovir disoproxil fumarate vs emtricitabine/tenofovir disoproxil fumarate, both administered with efavirenz, in antiretroviral-naive Zambian patients with HIV-1 infection.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2013

At a glance

  • Drugs Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2013 New trial record
    • 03 Jul 2013 Primary endpoint 'Virological-response-rate' has been met.
    • 03 Jul 2013 Results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top